CytoGen, Inc. · KRX:217330

CytoGen, Inc. financial statements

CytoGen, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in KRW

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue26.1B10.9B3.18B760.8M347.8M642.7M798.9M1.23B205.9M849.8M
Cost of revenue20.4B8.08B2.34B565.6M290.6M772.3M985.6M913.3M179.5M586.9M
Gross profit5.61B2.83B846.2M195.2M57.3M-129.6M-186.7M312.2M26.4M262.9M
Research and development1.89B2.84B3.12B3.20B3.32B1.74B1.23B180.7M98.1M512.7M
Selling, general and administrative3.81B9.25B8.34B7.70B8.62B3.72B2.27B2.41B2.01B2.04B
Operating income-7.48B-14.0B-14.0B-11.3B-12.9B-6.59B-4.49B-2.63B-2.28B-2.61B
Depreciation and amortization3.17B1.66B1.62B1.22B1.01B1.04B976.7M432.4M263.9M289.1M
EBITDA-4.31B-12.4B-12.4B-10.1B-11.9B-5.54B-3.51B-2.20B-2.01B-2.32B
Interest expense2.33B2.09B3.04B3.93B2.66B222.0M0000
Income before tax-13.0B-17.9B-16.2B-18.7B-13.3B-5.01B-4.14B-2.60B-2.62B-2.15B
Income tax-121.1M000
Net income-12.3B-17.1B-15.8B-18.8B-10.9B-4.89B-4.14B-2.60B-2.62B-2.15B
Earnings per share, basic-533.70-741.97-711.80-1,054.05-621.09-867.75-734.98-461.35-595.78-557.37

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents11.0B31.2B54.8B595.7K30.3B11.1B10.1B2.09B4.40B2.80B
Short-term investments20.5B10.0B49.5M223.2M5.09B4.82B2.76B10.6B110.0M
Receivables6.08B3.95B474.0M588.2M88.9M936.7M1.34B457.5M99.9M575.3M
Inventory4.39B1.72B25.3M131.5M62.6M62.6M
Current assets43.2B48.1B56.0B19.4B43.6B22.4B14.3B20.2B4.72B3.62B
Property, plant and equipment6.83B4.98B3.10B2.81B1.73B2.37B1.63B728.8M906.1M
Goodwill4.83B4.83B2.72B5.71B
Total assets62.2B72.5B74.5B41.2B55.5B28.3B19.7B22.8B5.68B5.06B
Accounts payable3.46B1.67B206.6M189.2M112.6M67.1M141.5M69.2M51.3M
Current liabilities14.7B4.71B10.7B33.9B6.79B1.17B1.07B488.2M762.9M2.10B
Long-term debt10.7B13.3B8.37B20.4B5.38B1.93B
Total debt5.51B458.9M2.31B
Total liabilities26.2B23.9B21.1B35.6B32.5B9.97B1.80B711.5M947.5M4.59B
Shareholders' equity35.6B48.6B53.4B5.66B23.0B18.3B17.9B22.0B4.73B475.5M
Shares outstanding23.1M23.1M22.2M17.8M17.5M5.63M5.63M5.63M4.40M3.86M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-6.95B-9.53B-7.59B-6.38B-5.23B-4.47B-3.37B-2.77B-2.18B-2.36B
Capital spending-2.04B-1.12B-2.62B-745.0M-2.00B-269.7M-559.8M-1.31B-314.8M-347.3M
Free cash flow-8.99B-10.7B-10.2B-7.12B-7.23B-4.92B-3.93B-4.08B-2.49B-2.71B
Cash from investing-24.3B263.4M-6.65B-5.58B-4.09B11.7B-19.1B305.8M-232.4M
Cash from financing9.17B46.2B-1.04B30.0B9.64B-343.1M19.6B3.48B2.98B
Share buybacks6.50B40.0B1.12B409.9M20.0B3.49B
Change in cash-20.2B-24.7B39.0B-14.4B19.2B1.01B7.97B-2.31B1.60B384.9M